Skip to main content

Table 1 Baseline hemodynamic characteristics of male and female patients carrying a BMPR2 mutation.

From: Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension

  Male patients Female patients
  BMPR2 mutation non-carriers
n = 79
BMPR2 mutation carriers
n = 34
p BMPR2 mutation non-carriers
n = 188
BMPR2 mutation carriers
n = 81
p
Age at diagnosis, yrs (mean ± SD) 47.8 ± 17.1 34.6 ± 16.8 < 0.0001 47.4 ± 15.8 36.4 ± 14.9 < 0.0001
NYHA
I-II 21 (26.6%) 6 (17.6%) < 0.01 27 (14.4%) 11 (13.6%) 0.90
III 57 (72.2%) 21 (61.8%)   135 (71.8%) 55 (67.9%)  
IV 1 (1.3%) 6 (17.6%)   20 (10.6%) 10 (12.3%)  
Six-minute walk test distance, m 394 ± 96 377 ± 98 0.49 328 ± 119 343 ± 102 0.35
mPAP, mmHg 57 ± 14 63 ± 13 0.03 56 ± 14 62 ± 13 0.0007
RAP, mmHg 8 ± 5 8 ± 6 0.81 8 ± 5 8 ± 5 0.70
PCWP, mmHg 9 ± 3 8 ± 3 0.39 8 ± 3 8 ± 3 0.84
CI, L/min/m² 2.71 ± 0.83 2.17 ± 0.60 0.0003 2.45 ± 0.66 2.07 ± 0.62 < 0.0001
PVRi, mmHg/L/min/m² 19.6 ± 9.3 21.9 ± 13.5 0.29 20.5 ± 8.5 25.1 ± 11.1 0.0015
SvO 2, % 67 ± 8 59 ± 9 0.0015 61 ± 10 59 ± 10 0.09
Acute vasodilator responders, % 9 (11.4%) 1 (2.9%) 0.20 27 (14.4%) 1 (1.2%) < 0.01
  1. BMPR2: bone morphogenetic protein receptor type 2, PAH: pulmonary arterial hypertension, NYHA = New York Heart Association, mPAP = mean pulmonary artery pressure, RAP = right atrial pressure, PCWP = pulmonary capillary wedge pressure, CI = cardiac index, PVRi = indexed pulmonary vascular resistance, SvO2 = mixed venous oxygen saturation, NO = nitric oxide.
  2. Results are expressed as mean ± SD